{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T23:46:44Z","timestamp":1764114404919,"version":"3.46.0"},"reference-count":32,"publisher":"Georg Thieme Verlag KG","issue":"06","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Innovative Therapieans\u00e4tze wie die Poly-(ADP-Ribose)-Polymerase-Inhibitoren (PARPi) haben beim metastasierten kastrationsresistenten Prostatakarzinom (mCRPC), insbesondere in Kombination mit Androgenrezeptorblockern (ARPi), vielversprechende Ergebnisse gezeigt. Patienten profitieren \u2013 unabh\u00e4ngig von HRR-Genmutationen \u2013 von verbesserten radiologischen progressionsfreien \u00dcberlebensraten und einem l\u00e4ngeren Gesamt\u00fcberleben. Der Erfolg der Kombinationstherapie mit PARPi und ARPi h\u00e4ngt ma\u00dfgeblich von einem effektiven Therapie- und dem Nebenwirkungsmanagement ab. H\u00e4ufige h\u00e4matologische Nebenwirkungen sind An\u00e4mie, Leukopenie und Thrombozytopenie, w\u00e4hrend bei den nicht-h\u00e4matologischen Reaktionen insbesondere Fatigue, Diarrh\u00f6, \u00dcbelkeit und Obstipation von Bedeutung sind. Neben der Basisdiagnostik und pr\u00e4ventiven Ma\u00dfnahmen k\u00f6nnen, abh\u00e4ngig vom Schweregrad der Nebenwirkungen, Dosisanpassungen oder Therapiepausen erforderlich sein. Bei An\u00e4mie, der h\u00e4ufigsten Nebenwirkung, k\u00f6nnen unterst\u00fctzende Ma\u00dfnahmen wie Bluttransfusionen notwendig werden, um eine optimale Patientenversorgung sicherzustellen. Dieser Leitfaden bietet Uro-Onkologen praxisorientierte Handlungsempfehlungen f\u00fcr den klinischen Alltag.<\/jats:p>","DOI":"10.1055\/a-2669-8781","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:39:29Z","timestamp":1761608369000},"page":"552-568","source":"Crossref","is-referenced-by-count":0,"title":["Therapiemanagement des mCRPC bei Kombinationen mit PARP-Inhibitoren in der klinischen Praxis"],"prefix":"10.1055","volume":"56","author":[{"given":"Margitta","family":"Retz","sequence":"additional","affiliation":[{"name":"Urologische Klinik und Poliklinik, TUM Universit\u00e4tsklinikum Rechts der Isar, M\u00fcnchen, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Borkowetz","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Urologie, Universit\u00e4tsmedizin Rostock, Rostock, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Wittenzellner","sequence":"additional","affiliation":[{"name":"Medical Affairs Oncology, Pfizer Pharma GmbH, Berlin, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heja","family":"Aga-Barfknecht","sequence":"additional","affiliation":[{"name":"Medical Affairs Oncology, Pfizer Pharma GmbH, Berlin, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunhild","family":"von Amsberg","sequence":"additional","affiliation":[{"name":"Onkologisches Zentrum\/ Martini-Klinik, Universit\u00e4tsklinikum Hamburg-Eppendorf, Hamburg, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"AR Chaudhuri","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40265-022-01703-5","article-title":"PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer","volume":"82","author":"R Flippot","year":"2022","journal-title":"Drugs"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/j.seminoncol.2023.11.001","article-title":"Beyond BRCA: Diagnosis and management of homologous recombination repair deficient pancreatic cancer","volume":"51","author":"M LaRose","year":"2024","journal-title":"Semin Oncol"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919897537","article-title":"PARP inhibitor combinations in prostate cancer","volume":"12","author":"C Pezaro","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113249","article-title":"The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer","volume":"192","author":"N Agarwal","year":"2023","journal-title":"Eur J Cancer"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13046-016-0456-2","article-title":"Use of poly ADP-ribose polymerase (PARP) inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic","volume":"35","author":"A Cerrato","year":"2016","journal-title":"J Exp Clin Cancer Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/1758834011417039","article-title":"The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy","volume":"3","author":"M Javle","year":"2011","journal-title":"Ther Adv Med Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","article-title":"Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer","volume":"8","author":"M Asim","year":"2017","journal-title":"Nat Commun"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aam7479","article-title":"Enzalutamide-induced \u201cBRCAness\u201d and PARP inhibition is a synthetic lethal therapy for castration-resistant prostate cancer","volume":"10","author":"L Li","year":"2017","journal-title":"Sci Signal"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"e17037","DOI":"10.1200\/JCO.2022.40.16_suppl.e17037","article-title":"The effect of PARP inhibition on androgen receptor localization and activity in castration resistant prostate cancer","volume":"40","author":"E Nizialek","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","article-title":"Dual roles of PARP-1 promote cancer growth and progression","volume":"2","author":"MJ Schiewer","year":"2012","journal-title":"Cancer Discov"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"382","author":"J de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"N Agarwal","year":"2023","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer","volume":"41","author":"KM Chi","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer","volume":"1","author":"NW Clarke","year":"2022","journal-title":"NEJM Evid"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"K Fizazi","year":"2024","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","article-title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"N Agarwal","year":"2025","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(25)00683-X","article-title":"Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial","volume":"406","author":"K Fizazi","year":"2025","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"KN Chi","year":"2023","journal-title":"Ann Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"F Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"ref26","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103736","article-title":"Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer","volume":"9","author":"H Boelk","year":"2024","journal-title":"ESMO Open"},{"issue":"S 1","key":"ref27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-142069","article-title":"Acute Myeloid Leukemia\/Myelodysplastic Syndrome (AML\/MDS) Associated with PARP Inhibitors: A Real-World Analysis","volume":"136","author":"A Gajra","year":"2020","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.euo.2024.05.009","article-title":"Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy","volume":"8","author":"ND Shore","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/ijgc-2020-001288","article-title":"Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events","volume":"30","author":"A Madariaga","year":"2020","journal-title":"J Gynecol Cancer"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"NM Kuderer","year":"2006","journal-title":"Cancer"},{"issue":"S 5","key":"ref33","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO Clinical Practice Guidelines","volume":"27","author":"J Klastersky","year":"2016","journal-title":"Ann Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","article-title":"The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients","volume":"18","author":"J Kastersky","year":"2000","journal-title":"J Clin Oncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.6004\/jnccn.2015.0122","article-title":"Cancer-Related Fatigue, Version 2.2015","volume":"13","author":"AM Berger","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.annonc.2020.02.016","article-title":"Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment","volume":"31","author":"A Fabi","year":"2020","journal-title":"Ann Oncol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00761-020-00878-4","article-title":"Psychoedukation mit Krebspatienten. Hintergrund und wissenschaftliche Evidenz","volume":"27","author":"J Wei\u00df","year":"2021","journal-title":"Der Onkologe"},{"issue":"S 4","key":"ref39","doi-asserted-by":"crossref","first-page":"iv126","DOI":"10.1093\/annonc\/mdy145","article-title":"Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines","volume":"29","author":"P Bossi","year":"2018","journal-title":"Ann Oncol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO Guideline Update","volume":"38","author":"P Hesketh","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2669-8781.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T23:43:14Z","timestamp":1764114194000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2669-8781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":32,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2025,11,25]]},"published-print":{"date-parts":[[2025,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2669-8781","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"type":"print","value":"0001-7868"},{"type":"electronic","value":"1438-8820"}],"subject":[],"published":{"date-parts":[[2025,10,27]]}}}